UNSPSC 51272704: Dyclonine

This classification denotes an anesthetic agent with the molecular formula C18H27NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 078A24Q30O, chemically known as 1-propanone, 1- (4-butoxyphenyl)-3-(1-piperidinyl)-, hydrochloride but generally known as dyclonine, which bears US NIH Compound Identifier 3180. European Medicines Agency schedules Dyclonine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06432MIG.

UNSPSC 51272704 Dyclonine, a Commodity code, nominally covers a single local anesthetic agent, but the recent state and local opportunities posted under this code reflect a much broader procurement landscape around pharmaceuticals and pharmaceutical supply chain management. State and local governments soliciting under this code are actually purchasing finished pharmaceutical products—naloxone, generic multi-source drugs, and over-the-counter items—through competitive bidding, cooperative purchasing agreements, and exploratory market-intelligence initiatives. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving participating states and local facilities including Oregon). These jurisdictions are seeking suppliers capable of managing pharmaceutical inventory, meeting FDA and Drug Supply Chain Security Act compliance, coordinating with authorized wholesalers, and delivering products on recurring schedules to multiple locations across state and local health systems.

Geographic activity clusters in Florida, Texas, and Minnesota, with MMCAP's reach extending to Oregon and other participating jurisdictions. Recent representative opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries and a two-year initial term; Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription models outside traditional pharmacy benefit managers; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across multiple state and local facilities, with pricing weighted at 75 percent and contract effectiveness set for July 1, 2026. Vendors pursuing these opportunities must hold FDA and cGMP certifications, maintain relationships with authorized wholesalers, and meet insurance and compliance standards including workers' compensation and commercial general liability coverage.